Men who are treated for prostate cancer with hormone-targeted therapy have a higher risk of developing kidney problems, a new study suggests. The treatment, known as androgen deprivation therapy, lowers the risk of death among men with advanced, aggressive prostate cancer.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.